查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886994

mRNA疗法市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，以及2024年至2032年的预测

mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 请询问到货日

价格

mRNA疗法市场成长驱动因子

全球mRNA疗法市场正经历快速发展，这得益于前所未有的科学进步、不断扩展的生物技术以及在新冠疫情期间mRNA疫苗的成功商业化。根据最新的市场研究，在强劲的研发活动和mRNA疫苗日益普及的推动下，全球mRNA疗法市场预计将在2024年达到89.1亿美元。然而，随着新冠疫苗需求的正常化和全球疫苗接种计画的调整，预计到2025年，该市场规模将萎缩至60.1亿美元。儘管目前市场暂时萎缩，但在创新、治疗应用拓展和研发管线加速的推动下，预计到2032年，mRNA市场将快速增长至214.5亿美元，2025年至2032年的复合年增长率将达到19.9%。

mRNA技术从根本上改变了製药业的格局。曾经被视为实验性平台的mRNA技术，如今已迅速发展成为传染病、癌症、罕见遗传疾病和个人化医疗领域的变革性技术。 mRNA新冠疫苗Comirnaty（辉瑞/BioNTech）和Spikebax（Moderna）的成功上市，充分展现了mRNA疗法的潜力，并在全球市场树立了良好的口碑。

北美地区在2024年以35.12%的市场占有率（价值31.3亿美元）引领全球市场，这得益于世界一流的研究基础设施、充足的公共和私人资金，以及Moderna、辉瑞、BioNTech和葛兰素史克等主要製药创新企业的强大实力。

2025年的下滑反映了新冠疫苗接种活动的缩减。然而，从2026年开始，随着各种研发管线接近商业化，预计市场将再次实现强劲的两位数成长。

推动市场成长的因素

1. mRNA疗法的优点

与小分子化合物、DNA疫苗和传统生物製剂相比，mRNA疗法具有若干独特的优势。

  • 快速的研发週期
  • 强大的免疫反应
  • 安全性优势（不整合到宿主基因组）
  • 低剂量高效
  • 对新株的高适应性

这些优势正在加速针对流感、呼吸道合胞病毒（RSV）、痘病毒、寨卡病毒、疟疾和爱滋病等传染病的mRNA疫苗的研发。癌症疫苗和蛋白质替代疗法领域也取得了进展。

2.应用领域拓展至疫苗以外

虽然疫苗目前占市场收入的主导地位，但mRNA疗法正在拓展至以下领域：

  • 肿瘤学（例如，个人化癌症疫苗）
  • 遗传性疾病（例如，酵素替代疗法）
  • 蛋白质疗法
  • 心血管疾病
  • 自体免疫疾病

预计从2027年起，製药领域将成为成长最快的类别，首个mRNA药物预计将于2027年上市，mRNA药物市场预计将在2027年至2032年间以118.7%的复合年增长率增长，到2032年达到20亿美元。

市场限制因子

1. 储存与稳定性挑战

mRNA分子需要超低温才能维持稳定性。这阻碍了冷链基础设施有限的地区，特别是低收入国家，采用mRNA技术。

2. 高昂的生产成本

mRNA的生产涉及以下流程：

  • 多重纯化工艺
  • 专用设施
  • 复杂的脂质奈米颗粒（LNP）製剂
  • 严格的监理合规要求

这些因素需要大量的资本投入，并限制了全球产能。

3. 监管与公众接受度的挑战

mRNA药物的监管框架仍在不断发展中。儘管有强而有力的科学支持，但部分人士仍持怀疑态度，尤其是在新型疫苗技术方面。

主要市场趋势

mRNA在药物研发的应用日益广泛

全球临床试验数量显着成长，截至2022年，约40%的I期临床试验是基于mRNA技术。企业将mRNA应用于以下领域：

  • 个人化癌症疫苗
  • 肿瘤内注射
  • 免疫疗法

众多合作、收购和协作表明，整个产业正在建立强大的研发管线。

递送技术的突破性创新

脂质奈米颗粒 (LNP)、聚合物和阳离子奈米颗粒正在推动以下方面的改进：

  • mRNA 稳定性
  • 标靶递送
  • 细胞摄取

这些创新降低了毒性，并扩大了治疗应用范围。

市场区隔分析

依类型

预防（疫苗）－预计 2024 年市占率最大

预计 2024 年，疫苗细分市场将占最大的市场占有率，这主要得益于 COVID-19 疫苗和呼吸道合胞病毒 (RSV) 疫苗的批准。

已核准的产品包括：

  • Comirnaty（辉瑞/BioNTech）
  • Spikebax（Moderna）
  • mRESVIA（Moderna - 呼吸道合胞病毒疫苗）

正在研发的非新冠疫苗包括：

  • 季节性流感疫苗（mRNA-1010）
  • 猴痘疫苗
  • 疟疾疫苗
  • 鉅细胞病毒 (CMV) 疫苗

药物/药物 - 成长最快的领域

随着 mRNA 疗法的商业化，预计从 2027 年起将快速成长，尤其是在肿瘤领域。

依应用领域

传染病领域 - 截至目前处于领先地位2024年

该领域占领先地位，因为截至2025年初，所有核准的mRNA产品均针对传染病。

肿瘤领域－高成长领域

多种癌症疫苗正在研发中，包括BioNTech公司用于治疗非小细胞肺癌（NSCLC）的BNT116。

依分销管道

  • 由于疫苗接种计划，医院药房将在2024年发挥主导作用。
  • 随着核准产品的增加，零售药局预计也将成长。

区域展望

北美 - 市场领导者（2024 年市场规模：31.3 亿美元）

主要驱动因素

  • 大量政府资金支持（例如，2025 年 Moderna 获得 5.9 亿美元资助）
  • 强大的生物技术新创企业生态系统
  • 快速的监管审批
  • 高度的认知度与应用率

欧洲

德国和法国引领该地区，是 BioNTech、CureVac 和赛诺菲等主要公司的所在地。

亚太地区

这是成长最快的地区，主要受以下因素驱动：

  • 中国于2023年核准了首款国产mRNA新冠疫苗
  • 对癌症治疗测试的大量投资
  • 製造与研发合作

其他

随着拉丁美洲、中东和非洲医疗基础设施的发展，这些地区对疫苗的兴趣日益浓厚。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 概述：mRNA技术的进展
  • mRNA疗法的未来成长前景
  • 主要公司产品线分析
  • 主要产业趋势，包括併购和合作
  • 关税对市场的影响

第五章：全球mRNA疗法市场分析、洞察与展望预测（2019-2032）

  • 市场分析、洞察与预测 - 依类型划分
    • 预防性药物（疫苗）
      • 新冠疫苗
      • 非新冠疫苗
    • 药品
  • 市场分析、洞察与预测 - 依应用划分
    • 肿瘤学
    • 传染病
    • 其他
  • 市场分析、洞察与预测 - 依分销管道划分
    • 医院药房
    • 药局和零售药房
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北部美洲
    • 欧洲
    • 亚太地区
    • 其他

第六章 北美mRNA疗法市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲mRNA疗法市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区

第八章 亚太地区mRNA疗法市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：其他mRNA疗法市场分析、洞察与预测（2019-2032）

第十章：竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • Moderna Inc.
  • BioNTech
  • 辉瑞公司
  • CureVac SE
  • 葛兰素史克公司
  • 赛诺菲
  • Omega Therapeutics
  • Strand治疗学
  • 免疫治疗学
Product Code: FBI113411

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market is undergoing a period of rapid evolution, driven by unprecedented scientific advancements, expanding biotechnology capabilities, and successful commercialization of mRNA-based vaccines during the COVID-19 pandemic. According to the latest market intelligence, the global mRNA therapeutics market size reached USD 8.91 billion in 2024, supported by robust R&D activities and rising acceptance of mRNA vaccines. However, the market is projected to decrease to USD 6.01 billion in 2025 due to normalization in COVID-19 vaccine demand and shifts in immunization programs worldwide. Despite this temporary contraction, the market is expected to surge to USD 21.45 billion by 2032, driven by innovation, expanding therapeutic applications, and accelerating pipeline development, achieving a CAGR of 19.9% between 2025 and 2032.

The mRNA field has fundamentally reshaped the pharmaceutical landscape. What was once considered an experimental platform has rapidly emerged as a transformational technology capable of addressing infectious diseases, cancer, rare genetic disorders, and personalized medicine. The successful deployment of mRNA COVID-19 vaccines-Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna)-validated the potential of mRNA-based therapeutics and established strong global market confidence.

North America dominated the global market with a 35.12% share in 2024, valued at USD 3.13 billion, owing to its world-leading research infrastructure, substantial public and private funding, and strong presence of major pharmaceutical innovators such as Moderna, Pfizer, BioNTech, and GSK.

The decline in 2025 reflects reduced COVID-19 vaccination campaigns. However, post-2026, the market is anticipated to return to strong double-digit expansion as diverse pipelines move closer to commercialization.

Drivers Shaping Market Growth

1. Advantages of mRNA Therapeutics

mRNA therapies offer several unique advantages over small molecules, DNA vaccines, and conventional biologics:

  • Rapid development timeline
  • Strong immune response
  • Safety advantages (no integration into host genome)
  • High potency with small dosages
  • Easy adaptability to new strains

These benefits are accelerating the development of mRNA vaccines for infectious diseases like influenza, RSV, Mpox, Zika, malaria, and HIV, as well as therapeutic vaccines for cancer and protein-replacement therapies.

2. Expanding Applications Beyond Vaccines

Though vaccines dominate current market revenues, mRNA therapies are expanding into:

  • Oncology (e.g., personalized cancer vaccines)
  • Genetic diseases (e.g., enzyme replacement therapies)
  • Protein therapy
  • Cardiovascular disease
  • Autoimmune disorders

The drugs/medications segment is expected to become the fastest-growing category post-2027, supported by the anticipated launch of the first mRNA drug in 2027 and projections that the mRNA drug market will reach USD 2 billion by 2032 at a CAGR of 118.7% from 2027 to 2032.

Market Restraints

1. Storage and Stability Challenges

mRNA molecules require ultra-cold temperatures for stability. This continues to hinder adoption in regions with limited cold-chain infrastructure, particularly low-income countries.

2. High Manufacturing Costs

mRNA production involves:

  • Multiple purification steps
  • Specialized facilities
  • Complex lipid nanoparticle (LNP) formulation
  • Stringent regulatory compliance

These factors contribute to high capital expenditures and limited global production capacity.

3. Regulatory and Public Acceptance Issues

The regulatory framework for mRNA drugs is still evolving. Despite strong scientific backing, skepticism persists among certain segments of the population, particularly regarding new vaccine technologies.

Key Market Trends

Growing Adoption of mRNA in Drug Development

There has been substantial growth in clinical trials globally, with approximately 40% of mRNA-based clinical trials in Phase I as of 2022. Companies are using mRNA for:

  • Personalized oncology vaccines
  • Intratumoral injections
  • Immunotherapies

Multiple partnerships, acquisitions, and collaborations indicate a strong pipeline across the industry.

Breakthrough Innovations in Delivery Technologies

LNPs, polymers, and cationic nanoparticles are improving:

  • mRNA stability
  • Targeted delivery
  • Cellular uptake

These innovations reduce toxicity and allow broader therapeutic applications.

Segmentation Analysis

By Type

Prophylactic (Vaccines) - Dominant in 2024

The vaccines segment accounted for the highest share in 2024 due to COVID-19 and RSV vaccine approvals.

Approved products include:

  • Comirnaty (Pfizer/BioNTech)
  • Spikevax (Moderna)
  • mRESVIA (Moderna - RSV vaccine)

Non-COVID vaccines in the pipeline include:

  • Seasonal influenza (mRNA-1010)
  • Mpox
  • Malaria
  • Cytomegalovirus (CMV)

Drugs/Medications - Fastest Growing Segment

Expected boom after 2027 as mRNA therapeutics enter commercialization, especially in oncology.

By Application

Infectious Diseases - Leading in 2024

Because all approved mRNA products as of early 2025 target infectious diseases, this segment dominates.

Oncology - High Future Growth

Multiple cancer vaccines are in development, including BioNTech's BNT116 for NSCLC.

By Distribution Channel

  • Hospital Pharmacies dominated in 2024 due to vaccination programs.
  • Retail Pharmacies expected to grow with broader product approvals.

Regional Outlook

North America - Market Leader (2024 Value: USD 3.13 Billion)

Key drivers:

  • Significant government funding (e.g., USD 590 million to Moderna in 2025)
  • Strong biotech startup ecosystem
  • Rapid regulatory approvals
  • High awareness and adoption

Europe

Germany and France lead the region with major companies such as BioNTech, CureVac, and Sanofi.

Asia Pacific

Fastest-growing region, driven by:

  • China's approval of its first homegrown mRNA COVID-19 vaccine in 2023
  • High investment in oncology trials
  • Partnerships for manufacturing and development

Rest of the World

Latin America and Middle East & Africa show rising interest as healthcare infrastructure improves.

Competitive Landscape

Major players include:

  • Moderna Inc.
  • BioNTech SE
  • Pfizer Inc.
  • CureVac SE
  • GSK plc.
  • Sanofi
  • Omega Therapeutics
  • Strand Therapeutics

These companies are investing heavily in:

  • Clinical pipeline expansion
  • Delivery technology innovation
  • Large-scale biomanufacturing facilities
  • Cross-border partnerships

Conclusion

The global mRNA therapeutics market is transforming rapidly, driven by technological innovation, expanded pipeline applications, rising funding, and growing acceptance of mRNA-based medicines. While the market dips from USD 8.91 billion in 2024 to USD 6.01 billion in 2025, it is set to rebound strongly, reaching USD 21.45 billion by 2032. With breakthroughs expected across oncology, infectious diseases, and rare genetic disorders, mRNA technology is positioned to become one of the most influential healthcare innovations of the 21st century.

Segmentation

By Type

  • Prophylactic (Vaccines)
    • COVID-19 Vaccines
    • Non-COVID-19 Vaccines
  • Drugs/Medications

By Application

  • Oncology
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Others

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in mRNA Technology
  • 4.2. Future Growth Prospects for mRNA Therapeutics
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Prophylactic (Vaccines)
      • 5.1.1.1. COVID-19 Vaccines
      • 5.1.1.2. Non-COVID-19 Vaccines
    • 5.1.2. Drugs/Medications
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Infectious Diseases
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Prophylactic (Vaccines)
      • 6.1.1.1. COVID-19 Vaccines
      • 6.1.1.2. Non-COVID-19 Vaccines
    • 6.1.2. Drugs/Medications
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Infectious Diseases
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Prophylactic (Vaccines)
      • 7.1.1.1. COVID-19 Vaccines
      • 7.1.1.2. Non-COVID-19 Vaccines
    • 7.1.2. Drugs/Medications
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Prophylactic (Vaccines)
      • 8.1.1.1. COVID-19 Vaccines
      • 8.1.1.2. Non-COVID-19 Vaccines
    • 8.1.2. Drugs/Medications
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Infectious Diseases
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Prophylactic (Vaccines)
      • 9.1.1.1. COVID-19 Vaccines
      • 9.1.1.2. Non-COVID-19 Vaccines
    • 9.1.2. Drugs/Medications
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Infectious Diseases
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Pfizer Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. CureVac SE
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. GSK plc
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Sanofi
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Omega Therapeutics
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Strand Therapeutics
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Immunomic Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 3: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 4: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 7: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 8: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 9: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 12: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 13: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 17: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 18: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 23: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 24: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

List of Figures

  • Figure 1: Global mRNA Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global mRNA Therapeutics Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global mRNA Therapeutics Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global mRNA Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 6: North America mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 8: North America mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 9: North America mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 10: North America mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America mRNA Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America mRNA Therapeutics Market Value Share (%), By Country, 2024
  • Figure 14: Europe mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 16: Europe mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 17: Europe mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 18: Europe mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 25: Asia Pacific mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Rest of the World mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Rest of the World mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 32: Rest of the World mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 33: Rest of the World mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 34: Rest of the World mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Rest of the World mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Global mRNA Therapeutics Market Share (%), By Company, 2024